| Literature DB >> 29776332 |
Delia M Braun1, Inn Chung1, Nick Kepper1, Katharina I Deeg1, Karsten Rippe2.
Abstract
BACKGROUND: The ends of linear chromosomes, the telomeres, comprise repetitive DNA sequences in complex with proteins that protects them from being processed by the DNA repair machinery. Cancer cells need to counteract the shortening of telomere repeats during replication for their unlimited proliferation by reactivating the reverse transcriptase telomerase or by using the alternative lengthening of telomeres (ALT) pathway. The different telomere maintenance (TM) mechanisms appear to involve hundreds of proteins but their telomere repeat length related activities are only partly understood. Currently, a database that integrates information on TM relevant genes is missing. DESCRIPTION: To provide a resource for studies that dissect TM features, we here introduce the TelNet database at http://www.cancertelsys.org/telnet/ . It offers a comprehensive compilation of more than 2000 human and 1100 yeast genes linked to telomere maintenance. These genes were annotated in terms of TM mechanism, associated specific functions and orthologous genes, a TM significance score and information from peer-reviewed literature. This TM information can be retrieved via different search and view modes and evaluated for a set of genes as demonstrated for an exemplary application.Entities:
Keywords: Alternative lengthening of telomeres (ALT); Pathway analysis; Telomerase; Telomere maintenance
Mesh:
Substances:
Year: 2018 PMID: 29776332 PMCID: PMC5960154 DOI: 10.1186/s12863-018-0617-8
Source DB: PubMed Journal: BMC Genet ISSN: 1471-2156 Impact factor: 2.797
Fig. 1Data sources of TM genes included in TelNet. Selected screening studies and other references that served as sources for TM genes are shown. In total TelNet currently includes over 2000 human genes and more than 1100 budding yeast genes. Histograms of the TelNet scores are displayed for the complete gene sets per species and colored by their TM significance annotation. Color scheme: blue, predicted TM genes; beige, genes from screening studies; orange, validated genes
Screening studies and database information included in TelNet for identification of TM genes
| Method | Organism / cell line | # genes/proteins | Ref. |
|---|---|---|---|
| Proteomics of isolated chromatin segments (PICh) | human / Wi38-VA13 HeLa 1.2.11 | 296 | [ |
| Quantitative telomeric chromatin isolation protocol (QTIP) | human / HeLa | 34 | [ |
| Protein network analysis surrounding telomere repeat binding factors, TRF1, TRF2, and POT1 using dual-tag affinity purification in combination with multidimensional protein identification technology liquid chromatography - tandem mass spectrometry (MudPIT LC-MS/MS) | human / 293 T | 211 | [ |
| Protein complementation assay (PCA/bimolecular fluorescent complementation (BiFC)) of shelterin compounds and ~ 12.000 candidate genes; GST-pulldown of FLAG-tagged genes | human / HTC75 | 339 | [ |
| siRNA mediated knockdown; APB formation | human / U2OS | 29 | [ |
| Proteomic analysis of deregulated genes upon telomere shortening caused by the telomerase inhibitor GRN163 | human / SK-N-MC | 99 | [ |
| QTRAP: kinase library screen | human / HeLa | 109 | [ |
| Telomerase regulators affecting its transcription | human / various | 53 | [ |
| Gene set with potential relevance to telomeres and the ALT pathway | human / various | 297 | [ |
| Telomerase activity signature | human | 43 | [ |
| GO annotation containing the term “telo” | human | 245 | [ |
| Haploid deletion screen, telomere length | yeast | 166 | [ |
| Telomere length-variation screen in deletion strains | yeast | 138 | [ |
| Screen of DAmP collection | yeast | 77 | [ |
| Telomerase null screen of yeast mutants | yeast | 270 | [ |
| Telomerase regulators from the Yeastract database | yeast | 35 | [ |
| GO annotation containing the term “telo” | yeast | 192 | [ |
Fig. 2TM part of the TelNet gene card view. Annotation fields and possible entries for TM significance, associated TelNet score, TM comment, TMM annotation, TM functions and TM phenotype are depicted
Calculation of the TelNet score
| Feature | Score |
|---|---|
| Identification in a TM related screen (added up if present in multiple screens) | 1 |
| TM significance is “validated” | 3 |
| If TM significance is “predicted”, the gene yields 10% of the orthologue’s | 0-1 |
| Cellular function contains the term “telomere” | 1.5 |
| A TM function is assigned (added up for multiple functions) | 0.5 |
| TM function is “shelterin”, “telosome” or “telomerase” | 0.5-2 |
The different features and their associated TelNet score are listed. The final value is calculated as the sum of the different entries and can reach a maximum value of 10
Fig. 3Typical TelNet workflow. Top: On the front page, the organism is selected. Middle: Three different search options, namely “quick search”, “list search” and “advanced card search” are available to retrieve a set of genes. Bottom: The resulting genes can be displayed as a scrollable list or as a series of single gene cards. In addition, an overview of the associated TM annotations is provided on the statistics page
Fig. 4Application of TelNet for a correlation analysis of telomere length and gene expression. Scatter plot showing the log2 ratio (tumor/normal) of gene expression versus the Spearman correlation coefficient Rho for gene expression and telomere length. For histograms of Rho and log2 ratio a Gaussian fit is shown with significance values defined from the 1%-tail of the fit. Genes that were either significantly (p < 0.01) up- (log2 ratio > 0.852) or downregulated (log2 ratio < − 0.782) or significantly (p < 0.01) correlated (Rho > 0.186) or anti-correlated (Rho < − 0.184) were colored in black. Genes above the significance thresholds that were present in the TelNet database are shown in red color
Genes with (anti-)correlations between telomere length and gene expression listed in TelNet
| Gene | Rho | log2 expr. Ratio | TM information from |
| ||
|---|---|---|---|---|---|---|
|
| 0.25 | 4.7E-04 | 0.21 | 4.4E-01 | Predicted from budding yeast homologue | 1 |
|
| 0.23 | 1.1E-03 | −0.26 | 3.6E-01 | Predicted from budding yeast homologue | 1 |
|
| 0.22 | 1.8E-03 | −1.02 | 8.6E-04 | Predicted from budding yeast homologue | 1 |
|
| 0.22 | 2.4E-03 | 0.21 | 4.5E-01 | Predicted from budding yeast homologue | 1 |
|
| 0.20 | 4.2E-03 | 0.35 | 2.3E-01 | Predicted from budding yeast homologue | 1 |
|
| 0.20 | 5.4E-03 | −0.25 | 3.8E-01 | Predicted from budding yeast homologue | 1 |
|
| 0.19 | 7.7E-03 | −0.63 | 3.5E-02 | Predicted from budding yeast homologue | 1 |
|
| 0.19 | 7.8E-03 | 0.16 | 5.4E-01 | Validated in human | 6 |
|
| −0.19 | 6.6E-03 | −0.08 | 7.2E-01 | Human screen for telomere shortening | 2 |
|
| −0.20 | 5.9E-03 | −0.30 | 2.9E-01 | Predicted from budding yeast homologue | 1 |
|
| −0.21 | 3.6E-03 | −0.14 | 5.9E-01 | Human screen for telomere shortening | 2 |
|
| −0.21 | 3.1E-03 | −0.18 | 5.0E-01 | Validated in human | 5 |
In a pan-cancer analysis, genes were identified that showed a significant (anti-)correlation (correlation coefficient Rho < − 0.184 or Rho > 0.186 and, p < 0.01) between telomere length and gene expression. For the calculations, the values for the ratios of tumor over normal tissue were used. The table shows those genes that were listed in the TelNet database with their TM information and TelNet scores